Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Invested Capital (2016 - 2025)

Historic Invested Capital for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to $70.7 million.

  • Niagen Bioscience's Invested Capital rose 10563.88% to $70.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.7 million, marking a year-over-year increase of 10563.88%. This contributed to the annual value of $46.1 million for FY2024, which is 6198.34% up from last year.
  • As of Q3 2025, Niagen Bioscience's Invested Capital stood at $70.7 million, which was up 10563.88% from $64.2 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Invested Capital high stood at $70.7 million for Q3 2025, and its period low was $20.8 million during Q2 2022.
  • In the last 5 years, Niagen Bioscience's Invested Capital had a median value of $29.8 million in 2024 and averaged $35.9 million.
  • As far as peak fluctuations go, Niagen Bioscience's Invested Capital crashed by 5069.53% in 2022, and later soared by 10898.17% in 2025.
  • Niagen Bioscience's Invested Capital (Quarter) stood at $31.7 million in 2021, then dropped by 9.63% to $28.7 million in 2022, then fell by 0.75% to $28.5 million in 2023, then soared by 61.98% to $46.1 million in 2024, then soared by 53.33% to $70.7 million in 2025.
  • Its Invested Capital stands at $70.7 million for Q3 2025, versus $64.2 million for Q2 2025 and $55.3 million for Q1 2025.